Literature DB >> 3190553

Imaging human atherosclerosis with 99mTc-labeled low density lipoproteins.

A M Lees1, R S Lees, F J Schoen, J L Isaacsohn, A J Fischman, K A McKusick, H W Strauss.   

Abstract

The feasibility of localizing human atherosclerotic plaques by gamma scintillation camera external imaging with technetium-99m-labeled low density lipoproteins (99mTc-LDL) was tested in 17 patients who had atherosclerosis. Imaging demonstrated focal accumulation of radiolabel consistent with 99mTc-LDL sequestration by plaques in the carotid, iliac, or femoral vessels of four patients 8 to 21 hours after intravenous injection of the radiopharmaceutical. Focal accumulation of 99mTc-LDL also appeared in the location of coronary lesions in four patients, but this accumulation could not be distinguished with certainty from residual blood pool radioactivity. When carotid endarterectomy specimens from six patients who received 99mTc-LDL 1 day before endarterectomy were examined, the specimens had focal accumulations of radiolabel, with two to four times greater radioactivity in some regions of each specimen than in others; this occurred whether or not the lesions were detected on the gamma camera images. Lesion composition may have determined whether accumulation was quantitatively sufficient to produce an external image. Histologically, the imaged carotid specimen had abundant foam cells and macrophages and poorly organized intramural blood consistent with a plaque hemorrhage; in contrast, nonimaged endarterectomy specimens were mature, fibrocalcific plaques. We conclude that: 1) 99mTc-LDL did accumulate in human atherosclerotic plaques; 2) in some patients, the accumulation of 99mTc-LDL was sufficient for detection by gamma camera imaging; 3) the amount of LDL that accumulated appeared to depend on lesion composition; and 4) the design of new radiopharmaceuticals with reduced residual blood pool activity relative to plaque accumulation should lead to improved external imaging of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190553     DOI: 10.1161/01.atv.8.5.461

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  39 in total

1.  Strategic targeting of atherosclerotic lesions.

Authors:  J Narula; R Virmani; A E Iskandrian
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

2.  Nuclear medicine 2000.

Authors:  O Schober
Journal:  Eur J Nucl Med       Date:  1992

Review 3.  Nuclear medicine and atherosclerosis.

Authors:  H Sinzinger; I Virgolini
Journal:  Eur J Nucl Med       Date:  1990

Review 4.  Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development.

Authors:  Thibaut Quillard; Peter Libby
Journal:  Circ Res       Date:  2012-07-06       Impact factor: 17.367

Review 5.  Targeting the vulnerable plaque: the evolving role of nuclear imaging.

Authors:  John R Davies; James F Rudd; Tim D Fryer; Peter L Weissberg
Journal:  J Nucl Cardiol       Date:  2005 Mar-Apr       Impact factor: 5.952

6.  Fluorodeoxyglucose and calcium uptake in the vascular wall: clinically relevant or sugar-coated pill?

Authors:  Barry L Zaret
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 5.952

Review 7.  Advances in detection and characterization of atherosclerosis using contrast agents targeting the macrophage.

Authors:  Michael J Lipinski; Juan Carlos Frias; Zahi A Fayad
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

Review 8.  Rationale for the rational development of new cardiac imaging agents.

Authors:  D D Miller
Journal:  Ann Nucl Med       Date:  1993-11       Impact factor: 2.668

Review 9.  Molecular imaging in cardiovascular disease: Which methods, which diseases?

Authors:  Jonathan R Lindner; Albert Sinusas
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

10.  Molecular imaging of atherosclerotic plaque with (64)Cu-labeled natriuretic peptide and PET.

Authors:  Yongjian Liu; Dana Abendschein; Geoffrey E Woodard; Raffaella Rossin; Kyle McCommis; Jie Zheng; Michael J Welch; Pamela K Woodard
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.